Feature | November 22, 2013

Lexiscan, Adenoscan May Put Patients at Risk for Heart Attack, Death

radiopharmaceuticals and tracers nuclear molecular imaging FDA lexiscan
November 22, 2013 — The U.S. Food and Drug Administration (FDA) is warning healthcare professionals of the rare but serious risk of heart attack and death with use of the cardiac nuclear stress test agents Lexiscan (regadenoson) and Adenoscan (adenosine). The FDA has approved changes to the drug labels to reflect these serious events and updated recommendations for use of these agents. At this time, data limitations prevent FDA from determining if there is a difference in risk of heart attack or death between Lexiscan and Adenoscan.
The Warnings and Precautions section of the Lexiscan and Adenoscan labels previously contained information about the possible risk of heart attack and death with use of these drugs. However, recent reports of serious adverse events in the FDA Adverse Event Reporting System (FAERS) database and the medical literature prompted approval changes to the drug labels to include updated recommendations for use.
Lexiscan and Adenoscan are FDA-approved for use during cardiac nuclear stress tests in patients who cannot exercise adequately. Lexiscan and Adenoscan help identify coronary artery disease (CAD). They do this by dilating the arteries of the heart and increasing blood flow to help identify blocks or obstructions in the heart’s arteries. Lexiscan and Adenoscan cause blood to flow preferentially to the healthier, unblocked or unobstructed arteries, which can reduce blood flow in the obstructed artery. In some cases, this reduced blood flow can lead to a heart attack.?
Doctors should screen all nuclear stress test candidates for their suitability to receive Lexiscan or Adenoscan, as well as avoid using these drugs in patients with signs or symptoms of unstable angina or cardiovascular instability, as these patients may be at greater risk for serious cardiovascular adverse reactions. Cardiac resuscitation equipment and trained staff should be available before administering Lexiscan or Adenoscan.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.
For more information: www.fda.gov

Related Content

Siemens Healthineers, Symbia Intevo SPECT/CT system, xSPECT Quant, RSNA 2016
Technology | SPECT-CT| October 18, 2016
At the 2016 annual meeting of the Radiological Society of North America (RSNA 2016), Siemens Healthineers will showcase...
Lantheus, flurpiridaz F-18, myocardial perfusion imaging, MPI, cardiac stress testing, ASNC 2016
News | Radiopharmaceuticals and Tracers| October 17, 2016
Lantheus Holdings Inc. announced in late September that sub-analysis data from the first Phase 3 study of flurpiridaz F...
GE Healthcare, Discovery MI PET/CT system, FDA clearance, RSNA 2016
Technology | PET-CT| October 05, 2016
GE Healthcare recently announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Discovery MI digital...
ASNC, SNMMI, position statement, myocardial perfusion PET, coronary artery disease
News | PET Imaging| September 01, 2016
September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of...
UltraSPECT, Xpress3.Cardiac, nuclear imaging, RWJPE, New Jersey, Robert Wood Johnson Physician Enterprise
News | SPECT Imaging| July 25, 2016
UltraSPECT Inc. announced recently that Robert Wood Johnson Physician Enterprise (RWJPE), a multi-specialty, community-...
ASNC, SNMMI, PET standard, Pet cardiac imaging, PET nuclear imaging, perfusion imaging

An example of a cardiac PET-CT imaging, should a color coded image of the left ventricle to help assess myocardial perfusion to detect ischemia using a Siemens scanner.

News | Nuclear Imaging| July 19, 2016
Cell>Point, license agreement, China, United Eastern Pharmaceutical, Oncardia imaging agent
News | Radiopharmaceuticals and Tracers| July 07, 2016
July 7, 2016 — Cell>Point announced in mid-June it has entered into an...
SNMMI, appropriate use criteria, AUC, PAMA, qualified provider-led entity, PLE
News | Clinical Decision Support| June 27, 2016
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has been named a qualified provider-led entity (PLE)...
Philips, SNMMI 2016, Vereos digital PET/CT, time-of-flight, IntelliSpace 8.0, nuclear imaging
News | Nuclear Imaging| June 14, 2016
Philips announced it would be showcasing a variety of nuclear imaging solutions at the Society of Nuclear Medicine and...
Siemens Healthineers, SNMMI '16, molecular imaging, syngo.via, Biograph Horizon PET/CT, mobile configuration
Technology | Nuclear Imaging| June 09, 2016
At the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Siemens Healthineers will...
Overlay Init